Sydnone-based prosthetic groups for radioiodination
The potential of Strained-Promoted Sydnone-Alkyne Cycloaddition (SPSAC) for radioiodination was evaluated with model cyclooctyne-conjugated peptides. Starting with a series of sydnones with varying N<sub>3</sub> and C<sub>4</sub> substitution, a preliminary kinetic study with non-radioactive iodinated compounds highlighted the superiority of an arylsydnone substituted by a chlorine atom in C<sub>4</sub> position. Interestingly, reaction rate up to 11 times higher than using an azide was achieved with the best system. Access to <sup>125</sup>I-labelled sydnones was granted with high efficiency from arylboronic acid precursors by copper catalyzed nucleophilic substitution. Application of SPSAC on the model peptide in radiotracer conditions showed the same trend than in non-radioactive kinetic study and complete reactions could be achieved within less than an hour for the best systems. These results are favorable for use in the production of radiopharmaceuticals with heavy halogens and increase the diversity of available bioorthogonal reaction for nuclear imaging and therapy.
Authors
- François Guérard (ORCID: https://orcid.org/0000-0001-9795-2785)
- Jean‐François Gestin (ORCID: https://orcid.org/0000-0002-2804-473X)
- Romain Eychenne (ORCID: https://orcid.org/0000-0002-7354-2455)
- Férid Haddad (ORCID: https://orcid.org/0000-0001-6971-5969)
- Ludovic Le Saux
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (FR)
- IMT Atlantique (FR)
- Nantes Université (FR)
Publication Details
- Journal
- Bioorganic & Medicinal Chemistry
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1016/j.bmc.2024.117904
- Citations
- 2
- Primary Topic
- Click Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.50
Funders
- Labex Iron
- European Cooperation in Science and Technology
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale
- Institut National Du Cancer
- Direction Générale de l’offre de Soins
- CHIST-ERA